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Identity 
Other names: CSPG2, DKFZp686K06110, ERVR, 
GHAP, PG-M, WGN, WGN1 




Versican is encoded by a single gene and is located on 
chromosome 5q12-14 in the human genome. The 
human VCAN gene is divided into 15 exons over 90-
100 kb. The structure of versican was originally 
deduced by the analysis of cDNA from a human 
placental library (Naso et al., 1994). The entire primary 
structures of versican have been generated from human, 
murine, bovine and chick cDNA clones. The chick 
form was originally named PG-M (Shinomura et al., 
1993). 
Transcription 
RNA splicing occurs in the two large exons encoding 
the GAG attachment sites. The region encoded by exon 
7 is called GAG alpha, the region encoded by exon 8, 
GAG beta. Four mRNA transcripts arise from 
alternative splicing, giving rise to V0, V1, V2 and V3. 
V0 possesses both exon 7 and exon 8, V1 possesses 
exon 8 but not exon 7, V2 possesses exon 7 but not 
exon 8; and V3 possesses neither exon 7 nor exon 8 
(Wight, 2002). 
The expression of the versican gene (CSPG2) is 
regulated by a promoter that harbors a typical TATA 
box and potential binding sites for several transcription 
factors, including AP1, AP2, CCAAT enhancer protein, 
TCF-4 and cAMP-responsive element (Naso et al., 
1994; Rahmani et al., 2006; Domenzain-Reyna et al., 
2009). Regulation of the versican gene through an 
androgen response element in the proximal promoter 
has been reported in prostate (Read et al., 2007). 
 
Adapted from Naso et al., 2004. 
 












Versican belongs to the extracellular matrix chondroitin 
sulphate proteoglycan family. 
The largest versican isoform (V0) consists of 3396 aa. 
The core protein can be divided into three domains: the 
globular N-terminal domain (G1), the central domain 
(G2) where glycosaminoglycan (GAG) chains attach, 
and the globular C-terminal domain (G3). The G1 
domain is composed of an immunoglobulin-like motif, 
followed by two tandem repeats which bind hyaluronan 
(HA). The G3 domain contains two EGF-like repeats, a 
lectin-like subdomain and a complement binding 
protein (CBP)-like subdomain. The central domain G2 
can be alternatively spliced to give rise to the four 
versican isoforms: V0 (containing both GAG alpha and 
GAG beta), V1 (containing GAG beta), V2 (containing 
GAG alpha) and V3, lacking any GAG subdomain 
(Wight, 2002). 
A new alternatively spliced versican isoform, referred 
to as V4, has been identified and found to be 
upregulated in human breast cancer (Kischel et al., 
2010). 
 
Posttranslational modifications (PTM): the consensus 
sequence for chondroitin sulphate attachment sites 
reveals the number of potential GAG attachment sites: 
the number of GAG chains attached to the protein core 
depends on the isoforms since the GAG alpha 
subdomain bears 12-17 chondroitin sulphate (CS) 
chains, whereas the GAG beta subdomain bears 5-8 CS 
chains (Ricciardelli et al., 2009). 
Expression 
Versican was initially identified in the culture medium 
of human IMR-90 lung fibroblasts (Zimmermann and 
Ruoslahti, 1989).  
Versican is highly expressed in tissue compartments 
undergoing active cell proliferation and migration. V0 
and V1 isoforms are highly expressed during 
embryonic development, and their expression decreases 
after tissue maturation. In adult tissues, versican is 
present in the loose connective tissues of various 
organs and often associated with the elastic fibre 
network. It is localized in most smooth muscle tissues, 
in cartilage, in the basal layer of the epidermis, and in 
blood vessels (Bode-Lesniewska et al., 1996). Versican 
V2 is abundant in the central nervous system  
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(Schmalfeldt et al., 2000). The V3 isoform has been 
identified at the mRNA levels but very scarcely at the 
protein level (Cattaruzza et al., 2002). 
Localisation 
Versican is a component of the extracellular matrix. 
Function 
The name versican comes from versatile, with regard to 
the diversity of biological actions of this highly 
interactive molecule that can be attributed both to the 
amino- and carboxy-terminal domains and to the GAGs 
side chains attached to the middle portion of the core 
protein. Versican is involved in the control of cell 
adhesion, proliferation, migration, apoptosis and in 
ECM assembly (Wight, 2002; Theocharis, 2008; 
Ricciardelli et al., 2009). Its domain organization 
allows modulation of a large variety of cell behaviours 
through interaction with a wide range of binding 
partners, including ECM components (HA, type I 
collagen, tenascin and fibronectin among others), 
chemokines, and cell surface proteins (CD44, integrin 
beta1, epidermal growth factor receptor) (Wu et al., 
2005). 
Versican belongs to the hyalectan family, characterized 
by its ability to bind hyaluronan. The overall consensus 
is that versican together with  
hyaluronan forms a pericellular matrix that modulates 
cell proliferation, adhesion and migration in conditions 
such as in development and wound healing cell. Some 
of these actions have been ascribed to specific domains 
in the molecule. Thus, overexpression of versican G1 
domain can enhance cell proliferation and reduce cell 
adhesion (Ang et al., 1999; Zhang et al., 1999). G3 
domain has also been involved in several processes like 
cell proliferation and invasion (Zhang et al., 1998; 
Yang et al., 2003; Zheng et al., 2004; Yee et al., 2007), 
and GAG chains have been considered partially 
responsible for the antiadhesive properties of versican 
(Yamagata and Kimata, 1994; Sakko et al., 2003). 
Cell proliferation.  Versican is associated with a 
proliferative cell phenotype and it is often found in 
tissues showing elevated proliferation such as in 
development and in a variety of tumours (Wight, 2002; 
Ricciardelli et al., 2009). Purified versican added to the 
culture media in a melanoma cell line induces 
proliferation (Touab et al., 2002). Silencing 
experiments with siRNA have lead to the same 
conclusion in vascular smooth muscle cells (Huang et 
al., 2006) and preadipocytes (Zizola et al., 2007). 
Cell adhesion. Versican is an anti-adhesive substrate 
(Yamagata and Kimata, 1994). The anti-adhesive role 
of versican has been also shown in melanoma cells 
(Touab et al., 2002), prostate carcinoma cells (Sakko et 
al., 2003) or neural crest cells (Dutt et al., 2006). This 
inhibitory effect on cell adhesion may be mainly due to 
the presence of the GAG chains that might create a 
 
more hydrated extracellular matrix less suitable for cell 
adhesion. 
Nevertheless, the G3 domain of versican has pro-
adhesive properties raising the possibility that different 
breakdown products might differentially affect cell 
adhesion (Wu et al., 2002). 
Cell migration and invasion. Versican can increase 
cell motility in embryonic as well as tumour cells. This 
activity may be mostly associated with its antiadhesive 
activities. Silencing of V0/V1 versican expression 
reduces cell migration in wound healing assays in 
smooth muscle cells (Huang et al., 2006), or in prostate 
cancer cells, where addition of purified versican to the 
cells caused an increase in the invasion ability 
(Ricciardelli et al., 2007). In glioma, treatment of the 
cells with TGF-beta2 caused an increase in cell 
migration associated to an increase in versican 
production (Arslan et al., 2007). In the nervous system 
and in axonal growth, the V2 splice variant inhibits 
axonal growth and migration (Schmalfeldt et al., 2000). 
Apoptosis. The effect of versican on apoptosis is 
complex and anti- as well as pro-apoptotic functions 
have been reported. Overexpression of the V1 versican 
isoform in cultured fibroblasts increases apoptotic 
resistance, but cells were also sensitized to a wide 
range of cytotoxic agents (LaPierre et al., 2007). 
Cell differentiation and epithelial-mesenchymal 
transition (EMT).  Versican modulates cell 
differentiation and morphogenesis, since it is involved 
in EMT interactions and in mesenchymal cell 
condensation required for organogenesis. V1 (but not 
V2) has been shown to trigger MET in fibroblasts by 
inducing a switch from N-cadherin to E-cadherin and 
subsequent acquirement of epithelioid phenotype. 
Silencing of endogenous versican prevents 
condensation and MET in metanephric mesenchyme 
(Sheng et al., 2006). Versican is highly expressed in the 
mesenchymal cell condensation area during 
development of cartilage, heart, hair follicles and 
kidney, and in vitro evidences show that versican V0 
and V1 isoforms are involved in the process of 
precartilage mesenchymal condensation and subsequent 
chondrogenesis (Kamiya et al., 2006). The requirement 
of versican in development is highlighted by the 
finding that deficiency of versican in a transgenic 
mouse model is embryonic lethal, due to defects on 
cardiac formation, limb mesenchymal aggregation and 
chondrogenesis (Williams et al., 2005). 
Others. In neural cells, versican plays an important 
role in regulating axonal guidance (Perissinotto et al., 
2000). It is also an important molecule in inflammatory 
processes since it is able to interact with immune cell 
receptors and chemokines (Hirose et al., 2001). 
Homology 
Versican belongs to the hyalectan gene family of 
proteoglycans that include aggrecan, neurocan and 
brevican. 
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Mutations 
Note 
No missense, regulatory, small and gross deletions and 
insertions, complex rearrangements, or repeat 
variations have been described.  
In this context, disruption of the versican gene in 
mouse and chick leads to severe cardiac defects and 
alterations in chondrogenesis in the hdf (heart defect) 
mouse. This animal model has lead to the conclusion 
that normal expression of the VCAN (Cspg2) gene is 
required for the successful development of the heart 
and for cartilage differentiation, leading to correct limb 
chondrogenesis (Mjaatvedt et al., 1998). 
Only mutations affecting the splicing of exons 7 and 8 
have been described associated to Wagner syndrome, a 
rare disorder belonging to the group of hereditary 
vitreoretinal degenerations (Miyamoto et al., 2005; 




Versican, specially the large V0 and V1 isoforms, is 
overproduced by many cancer types of all kind of 
origins: brain tumours, melanoma, osteosarcoma, 
breast, prostate, colon, lung, pancreatic, endometrial, 
oral and ovarian cancers. Versican is expressed by 
tumour stromal cells as fibroblasts, and also by tumour 
cells in melanoma, prostate, pancreatic, endometrial 
and ovarian carcinomas. Versican has a positive effect 
on cell proliferation, migration and invasion, and exerts 
a negative effect on cell adhesion. In cancer cells, it is 
also involved in the control of the epithelial-
mesenchymal transition. The expression of particular 
domains enhances angiogenesis and metastasis in 
several tumour models (Ricciardelli et al., 2009). 
Versican has also been involved in metastasis by 
playing a role in the immune response. Versican acts on 
macrophages through the Toll-receptor 2 (TLR2) 
inducing TNF-alpha secretion and provoking lung 
metastatic growth (Kim et al., 2009). 
Prognosis 
Elevated levels of versican are usually associated with 
relapse and poor patient outcome in many cancer types, 
including breast and prostate. 
Brain tumours 
Disease 
V2 is the major versican isoform of brain ECM and it is 
usually decreased in glioma ECM, whereas it is 
increased in tumour vessels. Since versican is 
antiadhesive, this may be related to marked local 
invasivity and rarity of extracranial metastasis of 
gliomas (Paulus et al., 1996). It has been described that 
versican in brain tumours originates from fibroblasts 




Versican is absent in benign melanocytic nevi, weakly 
to strongly positive in dysplastic nevi, being 
proportional to the degree of nuclear atypia, and 
intensely positive in primary malignant melanomas and 
metastatic melanomas. Versican is involved in the 
progression of melanomas and may be a reliable 
marker for clinical diagnosis (Touab et al., 2002; Touab 
et al., 2003; Gambichler et al., 2008). 
Oncogenesis 
In melanoma, AP-1 and TCF-4 binding sites are the 
main regulatory regions directing versican production 




Versican is overexpressed in breast carcinoma, and it is 
specially localized in the proliferating interstitial 
tissues, and in vascular and perivascular elastic tissues 
involved in carcinoma invasion (Nara et al., 1997). 
Relapse in women with node-negative breast cancer is 
related to the level of versican deposited in peritumoral 




Versican is localized to the periacinar and peritumoral 
fibromuscular stroma in sections of nonmalignant and 
malignant human prostate tissues. Versican is increased 
in early-stage prostate cancer. Patients with low 
versican concentration had significantly better 
progression-free survival than patients with high levels 
of versican (Ricciardelli et al., 1998). Versican is also 
overexpressed in benign prostate hyperplasia (BPH) 
(True et al., 2009). 
Colon tumours 
Disease 
DNA isolated from human colon carcinoma tissue 
exhibits a selective hypomethylation of versican gene, 
three times lower than that found in either normal colon 
or ulcerative colitis tissues (Adany and Iozzo, 1990). 
Colon adenocarcinoma is characterized by a 
remarkable increase in the concentration of versican, 
which is significantly modified at the post-translational 
level, i.e. the type, length and the sulphation pattern of 
the GAG chains (Theocharis, 2002). 
Oncogenesis 
Hypomethylation of the VCAN gene occurs in benign 
and malignant colon cancer compared to normal colon. 
These changes in methylation may occur prior to  
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malignant transformation and may be associated to 
increased versican levels in colon cancer. 
Lung carcinoma 
Disease 
Increased stromal versican is associated with tumour 
recurrence, higher tumour stage, and lymph node 
metastases (Pirinen et al., 2005). 
Pancreatic tumours 
Disease 
Versican presents a great increase (27-fold) in 
comparison to normal pancreas, which may be closely 
associated with the growth and aggressiveness of this 
carcinoma.  
Significant specific post-translational modifications 
were also observed regarding the type, hydrodynamic 
size, sulphation pattern and extent of uronate 




Stromal versican expression was significantly higher in 
the advanced-stage and high-grade cancers, lymph 
node metastasis and ovarian metastasis. Epithelial 
versican expression was significantly higher in patients 
with lymph node metastasis and lymph-vascular space 
involvement. The disease-free survival and overall 
survival rates of patients exhibiting high stromal 
versican expression were significantly lower than those 
of patients exhibiting low stromal versican expression 
(Kodama et al., 2007). 
Ovarian tumours 
Disease 
Elevated levels of versican have been associated with a 
poor prognosis of ovarian cancers (Ricciardelli and 
Rodgers, 2006). Ovarian clear cell carcinoma (OCCC) 
microarray signature contains versican, which is in part 
in part epigenetically regulated, as it was 
hypomethylated in OCCC cell lines (Yamaguchi et al., 
2010). VCAN overexpression is associated with 
increased microvessel density (MVD) and invasion 
potential, which may lead to poorer overall and 
progression-free survival and platinum resistance 
(Ghosh et al., 2010). 
Oral carcinoma 
Disease 
High stromal versican expression predicts unfavourable 




Tumoral environment induces aberrant expression of 
versican in EL4 lymphoma cells (Rottiers et al., 1998). 
Atherosclerosis 
Disease 
Versican accumulates in atherosclerotic lesions and 
restenosis. Versican is also prominent at the borders of 
lipid-filled necrotic cores and at the plaque-thrombus 
interface of the atherosclerotic lesion, suggesting roles 
in lipid accumulation, inflammation, and thrombosis 
(Wight and Merrilees, 2004). 
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